Koirala Sushma, Khadka Sujan, Sapkota Sanjeep, Sharma Suprina, Khanal Santosh, Thapa Alina, Khadka Dhruba Kumar, Poudel Pramod
Department of Microbiology, National College (NIST), Tribhuvan University, Kathmandu, Nepal.
State Key Laboratory of Environmental Aquatic Chemistry, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China.
Biomed Res Int. 2021 Jun 8;2021:9958294. doi: 10.1155/2021/9958294. eCollection 2021.
The emergence of multidrug resistant (MDR) bacteria which is attributable to extended spectrum -lactamases (ESBLs) production of CTX-M types is an obvious problem worldwide. This study is aimed at determining the prevalence of CTX-M -lactamases producing multidrug resistant and among patients attending Bir Hospital. A cross-sectional study was conducted between April and September 2019 at Bir Hospital, Kathmandu, and Department of Microbiology, National College, Kathmandu, Nepal. A total of 5,690 different clinical specimens were subjected to cultural, microscopic, and biochemical analyses for the identification of the isolates. Antimicrobial susceptibility testing of the isolates was done, and MDR isolates were selected and processed for further ESBL confirmation by the combination disks method. All confirmed ESBL isolates were screened for CTX-M type -lactamases ( ) by PCR. Of the total 345 isolates (227 and 118 ), 232 were MDR. All 232 (67.24%) MDR isolates were suspected as ESBL producers on the screening test. However, on the phenotypic test, 135 (58.18%) of total MDR bacteria were confirmed as ESBL producers with the highest proportion in (59.37%). The major source of ESBL producers was urine. ESBL producing isolates were mostly identified from outpatients and patients belonging to age group 41-60. Gentamicin was found to be effective against ESBL producers. The prevalence of was (89.62%) with the highest frequency for (93.81%). High prevalence of ESBL of CTX-M types among MDR and was detected from clinical specimens of patients in Bir Hospital. This study warrants the need for the judicious use of antibiotics as well as emphasize the use of modern diagnostic tools for the early detection of MDR and ESBL producers to curb the emergence and spread of MDR and ESBL producing bacteria in the clinical settings of Nepal.
由CTX-M型超广谱β-内酰胺酶(ESBLs)产生导致的多重耐药(MDR)细菌的出现是一个全球性的明显问题。本研究旨在确定加德满都比尔医院就诊患者中产生CTX-M型β-内酰胺酶的多重耐药菌的流行情况。2019年4月至9月在尼泊尔加德满都比尔医院和加德满都国立学院微生物学系进行了一项横断面研究。总共5690份不同的临床标本进行了培养、显微镜和生化分析以鉴定分离株。对分离株进行了药敏试验,选择多重耐药分离株并通过组合纸片法进一步进行ESBL确认。所有确认的ESBL分离株通过PCR筛查CTX-M型β-内酰胺酶。在总共345株分离株(227株革兰氏阴性菌和118株革兰氏阳性菌)中,232株为多重耐药菌。在筛查试验中,所有232株(67.24%)多重耐药分离株被怀疑为ESBL产生菌。然而,在表型试验中,135株(58.18%)的总多重耐药菌被确认为ESBL产生菌,其中革兰氏阴性菌比例最高(59.37%)。ESBL产生菌的主要来源是尿液。产生ESBL的分离株大多从门诊患者和41-60岁年龄组的患者中鉴定出来。发现庆大霉素对ESBL产生菌有效。CTX-M型的流行率为(89.62%),其中CTX-M-15频率最高(93.81%)。从比尔医院患者的临床标本中检测到多重耐药革兰氏阴性菌和革兰氏阳性菌中CTX-M型ESBL的高流行率。本研究表明需要明智地使用抗生素,并强调使用现代诊断工具早期检测多重耐药菌和ESBL产生菌,以遏制尼泊尔临床环境中多重耐药菌和ESBL产生菌的出现和传播。